Riskpilot← Back to searchSign inGet full accessLOFOTEN SYNSSENTER AS
ASActiveOrg 888415602Vestfjordgata 17, 8300 SvolværRetail sale of medical and orthopaedic goods · NACE 4774Est. 20059 employees
Revenue 2024
NOK 13,6M
+12% vs 2023
EBITDA margin
8.7%
+34% vs 2023
Equity ratio
18.6%
Financial strength
Net profit 2024
NOK 455K
-12% vs 2023
| Revenue | NOK 13,6M | +12% |
| EBITDA | NOK 1,2M | +34% |
| Net profit | NOK 455K | -12% |
| Total assets | NOK 5,9M | +112% |
| Equity | NOK 1,1M | +75% |
| Employees | 9 | — |
Legal name
LOFOTEN SYNSSENTER AS
Org number
888415602
Legal form
Aksjeselskap
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
4. juli 2005
Share capital
NOK 100 000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Drive optisk forretning samt annet som naturlig faller inn under dette.
Address
Vestfjordgata 17, 8300 Svolvær
Phone
+4776067250
Email
post@specsavers.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 639 | 10 807 | 11 423 | 12 144 | 13 561 |
| Staff expenses | −2 767 | −3 238 | −3 364 | −3 648 | −4 405 |
| EBITDA | 1 325 | 676 | 986 | 878 | 1 174 |
| Depreciation & amort. | −500 | −154 | −246 | −153 | −539 |
| EBIT | 825 | 521 | 741 | 725 | 635 |
| Net financials | −100 | −54 | −41 | −67 | −155 |
| Profit before tax | 724 | 467 | 700 | 658 | 480 |
| Tax | 173 | 172 | 163 | 140 | 26 |
| Net profit | 551 | 296 | 537 | 518 | 455 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 813 | 3 491 | 3 911 | 2 795 | 5 932 |
| Equity | 838 | 1 133 | 1 683 | 631 | 1 103 |
| Long-term debt | 2 700 | 985 | 907 | 829 | 2 840 |
| Short-term debt | 1 275 | 1 372 | 1 321 | 1 335 | 1 990 |
| Total debt | 3 975 | 2 357 | 2 228 | 2 164 | 4 830 |
EBITDA margin
8.7%
This company
15.8%
Market median
-45% vs market
20202024
Equity ratio
18.6%
This company
38.2%
Market median
-51% vs market
20202024
Return on equity
41.3%
This company
18.4%
Market median
+124% vs market
20202024
Net profit margin
3.4%
This company
8.1%
Market median
-58% vs market
20202024
Asset turnover
2.29×
This company
1.12×
Market median
+104% vs market
20202024
Debt / equity
4.38×
This company
0.62×
Market median
-606% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
HT Deputy Member | Deputy Member | 2005 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (1) | ||
| Chairman | 2005 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lito Hadsel As
LOFOTEN SYNSSENTER AS Board members of LOFOTEN SYNSSENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tommy Bergvik | Chief Executive Officer | 0 companies |
| Hege Thorgersen Strøm | Deputy Member | 0 companies |
| Carl Gunnar Strøm | Chairman | 0 companies |
| Mathias Bergvik | Board of Directors | 0 companies |
| Lisbeth Johansen Bergvik | Chairman | 0 companies |